Abel Hall LLC’s INmune Bio INMB Stock Holding History

Abel Hall LLC’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$47.9K	Hold	24,559	–	–	0.01%	835
2026 Q2	$40K	Buy	+24,559	New	+$34K	0.01%	907

Other funds holding INMB

Modera Wealth Management Westwood, New Jersey $9.5B AUM 16% 1-Year Est. Return

Bill Few Associates Pittsburgh, Pennsylvania $485M AUM 17.8% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Leonteq Securities AG Zurich, Switzerland $2.44B AUM 50.17% 1-Year Est. Return

Close Asset Management London, United Kingdom $3.42B AUM 34.5% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Abel Hall LLC's INMB Position: Q3 2026 in Review

Abel Hall LLC held its INmune Bio (INMB) position steady in Q3 2026 at 24,559 shares worth $47.9K. The position accounts for 0.01% of the portfolio, ranked #835.

Abel Hall LLC first reported a position in INMB in Q2 2026 and has held it in 2 quarters since. 11 funds tracked by Wall St. Rank hold INMB as of Q3 2026.

Abel Hall LLC held 24,559 shares of INmune Bio worth $47.9K as of Q3 2026.
Abel Hall LLC left its INmune Bio share count unchanged in Q3 2026.
INmune Bio made up 0.01% of Abel Hall LLC's portfolio in Q3 2026, its #835 holding.
Abel Hall LLC first reported a position in INmune Bio in Q2 2026 and has held it in 2 quarters since.
11 funds tracked by Wall St. Rank held INmune Bio as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.